Canntab Therapeutics Ltd (fka CTABF)

[MjMilo]

Canntab's Extensive IP Portfolio – At the Core of Our Value
Proposition

Canntab has filed 13 patents in Canada and United States that cover a range of processes and formulations needed to create the Company’s hard pill formulations, including instant release, extended release, and bi -layered solutions.

In August the International Preliminary Report on Patentability (IPRP) indicated a positive finding of patentability for Canntab’s Instant Release Cannabidiol Formulation, meaning that, in their opinion, the Company’s formulation is not only patentable but also novel, non-obvious and useful.


About Canntab TherapeuticsCanntab Therapeutics Ltd. is a Canadian company engaged in the research and development of advanced, pharmaceutical-grade formulations of cannabinoids and terpenes. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace, formulated in multiple doses and time release combinations. Canntab’s proprietary hard pill cannabinoid formulations will provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication.Additionally, Canntab has applied for its Cannabis Research Licence in Canada. The research licence will likely be acquired before Canntab obtains Licensed Producer status, which will allow the Company to receive oil, and to begin preparing product submissions to Health Canada, and machines for full scale manufacturing.Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.